Clinical studies of advanced ovarian cancer patients comparing outcomes of mEOC with sEOC when treated with platinum based chemotherapy
| Type of study | No of patients | Patient group | Outcome | Ref. |
| Retrospective analysis | 47 mEOC, 94 sEOC | First line advanced | mEOC: RR 38.5% | Pectasides18 |
| sEOC: RR 70%. No significant difference in median OS or PFS | ||||
| Case-controlled study | 27 mEOC, 54 other histological types | First line advanced | mEOC: RR 26.3%, median PFS 5.7 months, OS 12 months | Hess5 |
| sEOC: RR 64.9%, PFS 14.1 months, OS 36.7 months | ||||
| Retrospective analysis | 19 mEOC | First line advanced | RR 41.5%, No PFS/OS data | Pisano19 |
| Retrospective analysis (multicentre) | 20 mEOC, 388 other histological types | Platinum-sensitive recurrent advanced disease | mEOC: RR 36.4%, median PFS 4.5 months | Pignata20 |
| Other subtypes: RR 62.6%, median PFS 8 months | ||||
| Meta-analysis of seven randomised ovarian trials | 264 mEOC, 8440 other histological types | First line advanced | mEOC: median OS 14.6 months | Mackay4 |
| sEOC: median OS, 40.8 months | ||||
| Meta-analysis of four phase III ovarian trials | 54 mEOC, 1064 other histological types (788 sEOC) | First line advanced | mEOC: RR 60%, median PFS 11.4 months, OS 21.6 months | Alexandre3 |
| sEOC: RR 81%, median PFS 17.5 months, OS 47.2 months | ||||
| Retrospective analysis (multicentre) | 73 mEOC, 3292 other histological types | First line advanced | mEOC: median PFS 7.0 months, OS 11.3 months | Tian21 |
| sEOC: PFS 16.7 months, OS 40.5 months |
mEOC, mucinous epithelial ovarian cancer; OS, overall survival; PFS, progression free survival; RR, response rate; sEOC, serous epithelial ovarian cancer.